Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US list price

(Uxbridge, Middlesex, 22 September 2025) –

Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. The UK would be the first country in Europe to make this medicine available for adults living with schizophrenia, a mental health disorder that affects approximately 1 in 100 people in the UK with nine times greater suicide risk.^1,2 The annual societal cost of schizophrenia is estimated at over £9 billion.³

Bristol Myers Squibb plans to launch this medicine at a UK list price equal to the US list price, to reflect the value of this medicine for patients and society.

Bristol Myers Squibb intends to submit a marketing authorisation application for xanomeline and trospium chloride to the Medicines and Healthcare products Regulatory Agency (MHRA) later this year, via the International Recognition Procedure (IRP). This fast-track route enables accelerated approval by leveraging its prior authorisation by the Food and Drug Administration (FDA).

Commenting on today’s statement, Guy Oliver, General Manager, Bristol Myers Squibb UK, says “Despite the UK’s challenging commercial environment, we are committed to working with the NHS, NICE and other authorities to make this medicine available to all eligible UK patients. However, to enable us to achieve this goal, a new approach is needed. We therefore call on the Government to collaborate with the life sciences sector to increase investment in new medicines and fully recognise the value that innovation brings to patients, society, and the UK’s long-term prosperity.”